eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2023
vol. 48
 
Share:
Send email
Share:
abstract:
Experimental immunology

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

Boyang Gao
1
,
Haojie Shentu
2
,
Suyong Sha
3
,
Dongying Wang
4
,
Xi Chen
2
,
Zhenwei Huang
2
,
Nan Dong
2
,
Haijia Lai
2
,
Jianying Xu
2
,
Xiaoshuai Zhou
5

  1. Wenzhou Medical University, Wenzhou, Zhejiang, China
  2. The Medical Imaging College, Hangzhou Medical College, Hangzhou, Zhejiang, China
  3. Emergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China
  4. The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
  5. Department of Anus & Intestine Surgery, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China
Cent Eur J Immunol 2023; 48 (4): 301-310
DOI: https://doi.org/10.5114/ceji.2023.134257
Online publish date: 2024/01/09
View full text Get citation
 
PlumX metrics:
Introduction:
A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD.

Material and methods:
We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP).

Results:
After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI:2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively.

Conclusions:
IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.

keywords:

Crohn’s disease, IL-12/23 inhibitors, IL-23 inhibitors, meta-analysis, biologics, RCT
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.